UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook

Cancer treatment reviews, 2020-06, Vol.86, p.102017-102017, Article 102017

2020

Volltextzugriff (PDF)

Bevacizumab in Non–Small Cell Lung Cancer

Clinical cancer research, 2007-08, Vol.13 (15), p.4613s-4616s

Sandler, Alan

2007

Volltextzugriff (PDF)

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

The New England journal of medicine, 2018-12, Vol.379 (23), p.2220-2229

2018

Volltextzugriff (PDF)

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

The Lancet (British edition), 2016-04, Vol.387 (10030), p.1837-1846

2016

Volltextzugriff (PDF)

The Role of MET Receptor Tyrosine Kinase in Non‐Small Cell Lung Cancer and Clinical Development of Targeted Anti‐MET Agents

The oncologist (Dayton, Ohio), 2013-02, Vol.18 (2), p.115-122

2013

Volltextzugriff (PDF)

Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study

Clinical cancer research, 2008-03, Vol.14 (5), p.1407-1412

2008

Volltextzugriff (PDF)

Recent progress in therapeutic antibodies for cancer immunotherapy

Current opinion in chemical biology, 2018-06, Vol.44, p.56-65

2018

Volltextzugriff (PDF)

Clinical Course of Advanced Non–Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599

Journal of clinical oncology, 2010-02, Vol.28 (6), p.949-954

2010

Volltextzugriff (PDF)

Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599

Journal of clinical oncology, 2008-01, Vol.26 (1), p.60-65

2008

Volltextzugriff (PDF)

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial

Journal of clinical oncology, 2015-03, Vol.33 (9), p.1000-1007

2015

Volltextzugriff (PDF)

Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501

Journal of clinical oncology, 2009-12, Vol.27 (35), p.6006-6011

2009

Volltextzugriff (PDF)

Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study

Journal of thoracic oncology, 2018-12, Vol.13 (12), p.1906-1918

2018

Volltextzugriff (PDF)

Invisible Barriers to Clinical Trials: The Impact of Structural, Infrastructural, and Procedural Barriers to Opening Oncology Clinical Trials

Journal of clinical oncology, 2006-10, Vol.24 (28), p.4545-4552

2006

Volltextzugriff (PDF)

Retrospective Evaluation of the Clinical and Radiographic Risk Factors Associated With Severe Pulmonary Hemorrhage in First-Line Advanced, Unresectable Non–Small-Cell Lung Cancer Treated With Carboplatin and Paclitaxel Plus Bevacizumab

Journal of clinical oncology, 2009-03, Vol.27 (9), p.1405-1412

2009

Volltextzugriff (PDF)

Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib

Journal of clinical oncology, 2008-03, Vol.26 (9), p.1472-1478

2008

Volltextzugriff (PDF)

TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2005-09, Vol.23 (25), p.5892-5899

2005

Volltextzugriff (PDF)

Inhibition of angiogenesis in the treatment of non‐small cell lung cancer

Cancer science, 2007-12, Vol.98 (12), p.1825-1830

2007

Volltextzugriff (PDF)

A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas

Clinical cancer research, 2008-07, Vol.14 (14), p.4517-4525

2008

Volltextzugriff (PDF)

Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2007-10, Vol.25 (30), p.4743-4750

2007

Volltextzugriff (PDF)

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2008-11, Vol.26 (33), p.5407-5415

2008

Volltextzugriff (PDF)

Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer

Journal of clinical oncology, 2006-05, Vol.24 (13), p.2038-2043

2006

Volltextzugriff (PDF)

Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications

Journal of clinical oncology, 2005-05, Vol.23 (14), p.3243-3256

2005

Volltextzugriff (PDF)

Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study

European journal of cancer (1990), 2018-09, Vol.101, p.201-209

2018

Volltextzugriff (PDF)

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

The New England journal of medicine, 2002-01, Vol.346 (2), p.92-98

2002

Volltextzugriff (PDF)

1 – 25 von 628

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(582)
Mit Volltextzugriff
(533)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(627)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(339)
Humans
(333)
Life Sciences & Biomedicine
(331)
Female
(188)
Male
(183)
Oncology
(183)
Biological And Medical Sciences
(158)
Medical Sciences
(158)
Middle Aged
(147)
Aged
(131)
Adult
(128)
Lung Neoplasms - Drug Therapy
(119)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(94)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(78)
Treatment Outcome
(77)
Pharmacology. Drug Treatments
(74)
Tumors
(62)
Antineoplastic Agents
(56)
Lung Neoplasms - Pathology
(56)
Aged, 80 And Over
(52)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook

Bevacizumab in Non–Small Cell Lung Cancer

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

The Role of MET Receptor Tyrosine Kinase in Non‐Small Cell Lung Cancer and Clinical Development of Targeted Anti‐MET Agents

Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study

Recent progress in therapeutic antibodies for cancer immunotherapy

Clinical Course of Advanced Non–Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599

Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial

Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501

Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study

Invisible Barriers to Clinical Trials: The Impact of Structural, Infrastructural, and Procedural Barriers to Opening Oncology Clinical Trials

Retrospective Evaluation of the Clinical and Radiographic Risk Factors Associated With Severe Pulmonary Hemorrhage in First-Line Advanced, Unresectable Non–Small-Cell Lung Cancer Treated With Carboplatin and Paclitaxel Plus Bevacizumab

Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib

TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

Inhibition of angiogenesis in the treatment of non‐small cell lung cancer

A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas

Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non–Small-Cell Lung Cancer

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer

Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications

Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

Suchergebnisse filtern